Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
Holding GMAB?
Track your performance easily
GMAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$22.18 - $32.89
Previous Close$22.75
Volume1.81M
Average Volume (3M)824.81K
Market Cap
$14.86B
Enterprise Value$10.87B
Total Cash (Recent Filing)kr28.14B
Total Debt (Recent Filing)kr770.00M
Price to Earnings (P/E)18.5
Beta0.53
Next Earnings
Nov 06, 2024EPS Estimate
$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.23
Shares Outstanding660,745,350
10 Day Avg. Volume1,321,778
30 Day Avg. Volume824,806
Standard Deviation0.10
R-Squared0.27
Alpha-0.00672
Financial Highlights & Ratios
Price to Book (P/B)0.48
Price to Sales (P/S)6.11
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$44.25Price Target Upside98.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Genmab News
PremiumCompany Announcements
Genmab Reports Strong Growth and Strategic Advances
PremiumCompany Announcements
Genmab’s Revenue Soars with Strategic Developments
PremiumCompany Announcements
Genmab Sees Strong DARZALEX Sales in Q3 2024
PremiumCompany Announcements
Baillie Gifford Acquires 4.99% Stake in Genmab A/S
PremiumCompany Announcements
Genmab A/S Announces Share Capital Expansion
PremiumCompany Announcements
Genmab Incentivizes Employees with Stock GrantsBulls Say, Bears Say
Bulls Say
Product InnovationGenmab's expertise in antibody design and progress with agents like EPKINLY demonstrate its innovative capabilities.
Regulatory ApprovalRybrevant is now FDA-approved for 2L EGFR+ NSCLC.
Sales GrowthDARZALEX sales in 3Q24 exceeded forecasts, showcasing strong growth.
Bears Say
Competition And Patent ExpiryGenmab's Cash Cow Darzalex is under growing pressure from GSK's Blenrep and the 2030 Patent Cliff.
Partnership And Development ConcernsBioNTech recently opted not to participate in the further development of the acasunlimab program under the parties’ existing collaboration agreement.
Sales And Market RisksRisks include potential slowing of DARZALEX sales and failure to obtain label extensions.
---
Ownership Overview
―
Insiders
1.18% Mutual Funds
0.08% Other Institutional Investors
97.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GMAB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was $22.18 and its highest was $32.89 in the past 12 months.
What is Genmab A/S’s market cap?
Currently, no data Available
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Nov 06, 2024 which is yesterday.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Aug 08, 2024. The company reported $0.317 earnings per share for the quarter, beating the consensus estimate of $0.311 by $0.006.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is $0.31.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 661,768,300 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of $0.317 in its last earnings report, beating expectations of $0.311. Following the earnings report the stock price went up 2.305%.
Which hedge fund is a major shareholder of Genmab A/S?
Among the largest hedge funds holding Genmab A/S’s share is Graham Capital Management, L.P.. It holds Genmab A/S’s shares valued at 595K.
---
Genmab Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$44.25 (98.12% Upside)
$44.25 (98.12% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 27.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.79%
12-Months-Change
Fundamentals
Return on Equity
18.45%
Trailing 12-Months
Asset Growth
18.45%
Trailing 12-Months
Company Description
Genmab A/S
Genmab A/S is an international biotech company. It is specialized in creating and developing differentiated antibody therapeutics for the treatment of cancer. The company currently markets DARZALEX monoclonal antibody for the treatment of patients with multiple myeloma and Arzerra monoclonal antibody for the treatment of chronic lymphocytic leukemia.
---
GMAB Company Deck
---
GMAB Earnings Call
Q2 2024
0:00 / 0:00
---
GMAB Stock 12 Month Forecast
Average Price Target
$44.25
▲(98.12% Upside)
Technical Analysis
Best Analysts Covering GMAB
1 Year
1 Year Success Rate
2/14 ratings generated profit
1 Year Average Return
-14.33%
assigned a buy rating 2 months ago
Copying Asthika Goonewardene's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -14.33% per trade.
---